Clarius Group LLC Reduces Holdings in Boston Scientific Co. (NYSE:BSX)

Clarius Group LLC lessened its holdings in Boston Scientific Co. (NYSE:BSX) by 3.2% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,070 shares of the medical equipment provider’s stock after selling 271 shares during the quarter. Clarius Group LLC’s holdings in Boston Scientific were worth $621,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. First Foundation Advisors acquired a new position in shares of Boston Scientific during the first quarter worth $25,000. Eagle Bay Advisors LLC lifted its stake in Boston Scientific by 542.1% during the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 309 shares during the period. Lynx Investment Advisory acquired a new position in Boston Scientific during the second quarter valued at $30,000. RiverPark Advisors LLC acquired a new stake in Boston Scientific during the first quarter worth about $30,000. Finally, Northwest Investment Counselors LLC acquired a new position in shares of Boston Scientific in the 1st quarter valued at $31,000. 89.07% of the stock is currently owned by institutional investors.

Insider Activity

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $74.12, for a total value of $517,579.96. Following the transaction, the executive vice president now owns 40,188 shares in the company, valued at $2,978,734.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $74.12, for a total value of $517,579.96. Following the completion of the sale, the executive vice president now owns 40,188 shares of the company’s stock, valued at $2,978,734.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Arthur C. Butcher sold 14,011 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $75.34, for a total value of $1,055,588.74. Following the completion of the transaction, the executive vice president now directly owns 20,197 shares in the company, valued at $1,521,641.98. The disclosure for this sale can be found here. Insiders have sold 34,960 shares of company stock worth $2,638,984 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

BSX stock traded down $0.22 during trading on Friday, reaching $75.33. 632,631 shares of the company’s stock were exchanged, compared to its average volume of 6,270,862. The company’s fifty day moving average price is $76.33 and its 200-day moving average price is $71.21. The firm has a market cap of $110.52 billion, a PE ratio of 63.30, a P/E/G ratio of 2.49 and a beta of 0.78. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $79.43.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, topping the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.80%. The firm had revenue of $4.12 billion for the quarter, compared to analysts’ expectations of $4.02 billion. During the same period in the previous year, the business earned $0.53 earnings per share. Boston Scientific’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, research analysts expect that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BSX. Evercore ISI increased their price objective on shares of Boston Scientific from $78.00 to $81.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 2nd. Mizuho lifted their price objective on Boston Scientific from $85.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, May 15th. Raymond James raised their target price on Boston Scientific from $85.00 to $91.00 and gave the company a “strong-buy” rating in a report on Thursday, July 25th. Needham & Company LLC boosted their price target on shares of Boston Scientific from $82.00 to $86.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, BTIG Research lifted their price target on Boston Scientific from $80.00 to $84.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $84.76.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.